600867.SH
通化东宝
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 7.95
−1.97%Year over year
Reported trailing growth
- Revenue
- +47.0%
- EBITDA
- —
- EBIT
- +3516.3%
- EPS
- +824.8%
- Free cash flow
- +310.2%
- Operating cash flow
- +109.1%
Forward estimates
Based on analyst estimates
- Revenue
- +15.2%
- EBITDA
- -41.3%
- EPS
- -56.7%
Three-year CAGR
- Revenue
- +2.0%
- EBITDA
- -1.6%
- EBIT
- -4.9%
- Net income
- -8.3%
- EPS
- -7.8%
- Free cash flow
- -22.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026